COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,086 Articles (22,658 medRxiv, 8,428 bioRxiv)

Most recent first Previous |  Page 1058: Articles 10571-10580  | Next

Measuring the impact of COVID-19 vaccination and immunity waning: a modelling study for Portugal
Caetano, C., Morgado, M. L., Patricio, P., Leite, A., Machado, A., Torres, A., Pereira, J. F., Namorado, S., Sottomayor, A., Peralta, A., Nunes, B.
10.1101/2021.12.10.21267618 — Posted: 2021-12-13
Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2
Titov, A., Shaykhutdinova, R., Shcherbakova, O. V., Serdyuk, Y. V., Sheetikov, S. A., Zornikova, K. V., Maleeva, A. V., Khmelevskaya, A., Dianov, D. V., Shakirova, N. T., Malko, D. B., Shkurnikov, M., Nersisyan, S., Tonevitsky, A., Khamaganova, E. G., Ershov, A. V., Osipova, E. Y., Nikolaev, R. V., Pershin, D. E., Vedmedskia, V. A., Maschan, M., Ginanova, V. R., Efimov, G. A.
10.1101/2021.12.12.21267518 — Posted: 2021-12-13
Symptoms persisting after hospitalization for COVID-19: 12 months interim results of the COFLOW study
Bek, M., Berentschot, J. C., Heijenbrok, M., Huijts, S., van Genderen, M. E., Vlake, J. H., van Bommel, J., Aerts, J. G. J. V., Ribbers, G. M., van den Berg, R. J. G., Hellemons, M. E., CO-FLOW collaboration Group
10.1101/2021.12.11.21267652 — Posted: 2021-12-13
Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review
Notarte, K. I., Guerrero-Arguero, I., Velasco, J. V., Ver, A. T., de Oliveira, M. H. S., Catahay, J. A., Khan, M. S. R., Pastrana, A., Juszczyk, G., Torrelles, J., Lippi, G., Martinez-Sobrido, L., Henry, B. M.
10.1101/2021.12.10.21267593 — Posted: 2021-12-13
Incidence of COVID-19 reinfection: an analysis of outpatient-based data in the United States of America
Azam, M., Pribadi, F. S., Rahadian, A., Saefurrohim, M. Z., Dharmawan, Y., Fibriana, A. I., Lestarini, I. A., Aljunid, S. M.
10.1101/2021.12.07.21267206 — Posted: 2021-12-13
Human serum from SARS-CoV-2 vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant in comparison to the original Wuhan strain and the Beta and Delta variants
Schubert, M., Bertoglio, F., Steinke, S., Heine, P. A., Ynga-Durand, M. A., Zuo, F., Du, L., Korn, J., Milosevic, M., Wenzel, E. V., Maass, H., Krstanovic, F., Polten, S., Pribanic-Matesic, M., Brizic, I., Piralla, A., Baldanti, F., Hammarstrom, L., Dubel, S., Sustic, A., Marcotte, H., Strengert, M., Protic, A., Pan Hammarstrom, Q., Cicin-Sain, L., Hust, M.
10.1101/2021.12.10.21267523 — Posted: 2021-12-13
Time-Varying Mortality Risk Suggests Increased Impact of Thrombosis in Hospitalized Covid-19 Patients
Lengerich, B. J., Nunnally, M. E., Aphinyanaphongs, Y. J., Caruana, R.
10.1101/2021.12.11.21267259 — Posted: 2021-12-13
The impact of remote home monitoring of people with COVID-19 using pulse oximetry: a national population and observational study.
Sherlaw-Johnson, C., Georghiou, T., Morris, S., Crellin, N., Litchfield, I., Massou, E., Sidhu, M., Tomini, S., Vindrola-Padros, C., Walton, H., Fulop, N.
10.1101/2021.12.10.21267613 — Posted: 2021-12-13
High correlation between binding IgG (anti-RBD/S) and neutralizing antibodies against SARS-CoV-2 six months after vaccination
Guiomar, R., Santos, A. J., Melo, A., Costa, I., Matos, R., Rodrigues, A. P., Kislaya, I., Silva, A. S., Roque, C., Silva, C., Aguiar, J., Graca, F., Graca, A., Machado, A.
10.1101/2021.12.10.21267607 — Posted: 2021-12-13 Discussion: Onsite
Resources Required for Implementation of SARS-CoV-2 Screening in Massachusetts K-12 Public Schools in Winter/Spring 2021
Lee, S. S., Weitz, M., Ardlie, K., Bantham, A., Schuckel, M. F., Goehringer, K., Hogue, C., Hosking, R., Mortimer, K., Saadat, A., Seaman-Chandler, J., Linas, B. P., Ciaranello, A. L.
10.1101/2021.12.10.21267568 — Posted: 2021-12-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).